The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer
Voluntarily agree to participate in the study and sign the informed consent;
Age ≥18 years old (including the threshold value);
Histologically confirmed invasive breast cancer with clinical stage T1c-T2(≥2cm)cN1-2M0 or T3cN0-2M0;
As assessed by the research Center, the subjects can tolerate and plan to undergo radical surgery for breast cancer and have not previously received any anti-tumor systemic therapy for breast cancer;
Bilateral invasive breast cancer;
Previous history of invasive breast cancer;
Previously had carcinoma in situ of the breast and received adjuvant endocrine therapy within 5 years of surgery;
Use of the investigational drug or major surgery within 4 weeks prior to study dosing;